Skip to content

Author

Jun-Wei Wang

We have 3 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Apoptotic Macrophage-Derived Vesicles Loaded with Oncolytic Virus for Tumor Therapy

Apoptotic macrophage-derived vesicles serve as an effective platform for oncolytic adenovirus delivery, improving anti-tumor efficacy in vitro and exhibiting significantly enhanced cytotoxicity against tumor cells.

Zhangquan Wang, Zhuo Yan, M. Tan et al. · 0 citations
Jul 2026

Abstract B005: ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors

The results support IND-enabling studies of ADT-030 as a monotherapy or in combination with standard-of-care treatments for patients with a broad range of RAS-driven cancers, and especially for patients who relapsed after RAS inhibitor treatment.

Xi Chen, D. S. Bandi, G. Nagaraju et al. · 0 citations
Jul 2026

Abstract A089: ADT-1004: A mechanistically distinct pan-RAS inhibitor with the potential to escape resistance and mitigate on-target toxicities that limit efficacy and safety of other RAS inhibitors

An orally bioavailable prodrug of ADT-1004, ADT-1004, demonstrated favorable tolerability and suppressed tumor growth in orthotopic and patient-derived xenograft models of pancreatic cancer, accompanied by reductions in activated RAS and p-ERK levels (Mol Cancer, 2025).

Junwei Wang, Xi Chen, Bandi D. S. Reddy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.